BC Centre for Excellence names Dr. Zabrina Brumme Director of Laboratory Program

August 14, 2018
British Columbia Centre for Excellence in HIV/AIDS

VANCOUVER, BC (Monday August 13, 2018) The BC Centre for Excellence in HIV/AIDS (BC-CfE) announced Dr. Zabrina Brumme has been appointed Director of Canada’s leading HIV laboratory program. Dr. Brumme will be on secondment from her position as Associate Professor in the Faculty of Health Sciences at Simon Fraser University (SFU), where she additionally holds a … Continue reading BC Centre for Excellence names Dr. Zabrina Brumme Director of Laboratory Program

Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis

August 13, 2018
Arbutus Biopharma Corporation

ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company’s lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced that their new drug application … Continue reading Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis

Aequus Announces Fully-subscribed $775,000 Equity Financing

August 9, 2018

VANCOUVER, BC. August 9, 2018 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it intends to complete a non-brokered private placement (the “Placement”) of 3,875,000 units of the Company (the “Units”) at … Continue reading Aequus Announces Fully-subscribed $775,000 Equity Financing

Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference

Arbutus Biopharma Corporation

WARMINSTER, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, will present a corporate update at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30 pm – 3:00 pm ET in New York. A live webcast of the presentation can be accessed through the Investor … Continue reading Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference

Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

August 8, 2018
Aquinox Pharmaceuticals, Inc

Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, … Continue reading Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Aug. 08, 2018 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox“) (NASDAQ:AQXP), a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the second quarter ending June 30, 2018. “At the end of last quarter, we announced that the Phase … Continue reading Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update

August 7, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, August 7, 2018.  Xenon management will host a conference call and live audio webcast at … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Xenon Pharmaceuticals Inc.

Novel Epilepsy Product Candidates – XEN1101 and XEN901 – Continue to Advance in the Clinic New XEN1101 Phase 1b TMS Pharmacodynamic Data to be Presented at upcoming European Congress on Epileptology BURNABY, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the … Continue reading Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

August 3, 2018
Arbutus Biopharma Corporation

Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated – Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of 2018 – All oral combination Phase 2 study of AB-506 and AB-452 expected to begin by the end of 2019 – Entering second … Continue reading Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial

July 26, 2018

Vancouver, British Columbia – July 25, 2018 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that the first patient in the RESTORE Phase 2 clinical trial for patients with moderate to severe Crohn’s disease has been … Continue reading Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial